Severe Hypoalbuminemia at Day 90 Predicts Worse Nonrelapse Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 384-393

  Kharfan Dabaja, Mohamed A ^a,b   Chavez, Julio C ^a   Yu, Daohai ^a   Zhu, Weiwei ^a   Fernandez Vertiz, Eduardo I ^a   Perkins, Janelle ^a   Shapiro, Jamie ^a   Bookout, Ryan ^a   Perez, Lia ^a,b   Fernandez, Hugo F ^a,b   Komrokji, Rami S ^a,b   Lancet, Jeffrey ^a,b   Brand, Linda ^a   Field, Teresa ^a,b   Ayala, Ernesto ^a,b   Janssen, William ^a   List, Alan F ^a,b   Anasetti, Claudio ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cumulative incidence of nonrelapse mortality; Hematopoietic cell allograft; Serum Albumin; Survival

Indexed keywords

ALBUMIN; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GLUCOCORTICOID; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOALBUMINEMIA; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROGNOSIS; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPOALBUMINEMIA; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79551685356     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.011     Document Type: Article

References (32)

1. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
2. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
3. Schetelig J., Bornhauser M., Schmid C., et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008, 26:5183-5191.
4. Kharfan-Dabaja M.A., Anasetti C., Santos E.S. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol Blood Marrow Transplant 2007, 13:373-385.
5. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
6. Leisenring W.M., Martin P.J., Petersdorf E.W., et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006, 108:749-755.
7. Leavey S.W., Strawderman R.L., Jones C.A., et al. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998, 31:997-1006.
8. Pifer T.B., McCullough K.P., Port F.K., et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002, 62:2238-2245.
9. Horwich T.B., Kalantar-Zadeh K., MacLellan R.W., et al. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008, 155:883-889.
10. Iwata M., Kuzuya M., Kitagawa Y., et al. Prognostic value of serum albumin combined with serum C-reactive protein levels in older hospitalized patients: continuing importance of serum albumin. Aging Clin Exp Res 2006, 18:307-311.
11. Goldwasser P., Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997, 50:693-703.
12. Lohsiriwat V., Lohsiriwat D., Boonnuch W., et al. Pre-operative hypoalbuminemia is a major risk factor for postoperative complications following rectal cancer surgery. World J Gastroenterol 2008, 14:1248-1251.
13. Leite H.P., Fisberg M., de Carvalho W.B., et al. Serum albumin and clinical outcome in pediatric cardiac surgery. Nutrition 2005, 21:553-558.
14. Nicholson J.P., Wolmarans M.R., Park G.R. The role of albumin in critical illness. Br J Anaesth 2000, 85:599-610.
15. Doweiko J.P., Nompleggi D.J. The role of albumin in human physiology and pathophysiology, Part III: albumin and disease states. J Parenter Enteral Nutr 1991, 15:476-483.
16. Franch-Arcas G. The meaning of hypoalbuminaemia in clinical practice. Clin Nutr 2001, 20:265-269.
17. Miller L.L., Bly G.G., Watson M.L., et al. The dominant role of the liver in plasma protein synthesis; a direct study of the isolated perfused rat liver with the aid of lysine-epsilon-C14. J Exp Med 1951, 94:431-453.
18. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
19. Sirott M.N., Bajorin D.F., Wong G.Y., et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993, 72:3091-3098.
20. Hickman D.M., Miller R.A., Rombeau J.L., et al. Serum albumin and body weight as predictors of postoperative course in colorectal cancer. J Parenter Enteral Nutr 1980, 4:314-316.
21. Peters T.J. Metabolism: Albumin in the body. All About Albumin: Biochemistry, Genetics, and Medical Applications 1996, 188-250. Academic Press Inc, San Diego, CA. T.J. Peters (Ed.).
22. Brenner D.A., Buck M., Feitelberg S.P., et al. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 1990, 85:248-255.
23. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112:1539-1542.
24. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
25. Pidala J., Kim J., Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:881-885.
26. Hingorani S.R., Seidel K., Lindner A., et al. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant 2008, 14:1365-1372.
27. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 13:273-278.
28. Goulmy E., Termijtelen A., Bradley B.A., et al. Y-antigen killing by T cells of women is restricted by HLA. Nature 1977, 266:544-545.
29. Randolph S.S., Gooley T.A., Warren E.H., et al. Female donors contribute to a selective graft versus leukemia effect in male recipients of HLA-matched related hematopoietic cell transplants. Blood 2004, 103:347-352.
30. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
31. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004, 103:353-359.
32. Yakoub-Agha I., de La Salmonière P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation. J Clin Oncol 2000, 18:963-971.